NCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
Clinical Trials
44 trialsNCT06160362 2023-12-07
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
Henan Cancer Hospital
Phase NA Unknown
NCT04825496 2023-09-21
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
NCT05797948 2023-04-04
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT05776407 2023-03-20
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
Chongqing University Cancer Hospital
Phase 1/2 Unknown
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT05727683 2023-02-14
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Unknown
NCT05322330 2023-02-09
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05379647 2022-05-18
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
Zhejiang University
Phase 1 Unknown
NCT05322733 2022-04-19
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05287984 2022-03-31
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04823091 2022-03-16
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT05155215 2021-12-13
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
NCT04264078 2021-06-28
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT04796675 2021-04-08
Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT04653493 2021-03-19
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Sabz Biomedicals
Phase 1 Unknown
NCT04796688 2021-03-15
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT04626726 2020-11-13
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04626765 2020-11-13
CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03302403 2020-10-08
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
First Affiliated Hospital of Wenzhou Medical University
Phase NA Unknown
NCT03778619 2020-07-28
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
GC Cell Corporation
Phase 1/2 Unknown
NCT04264039 2020-02-11
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT03110640 2019-11-27
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
First Affiliated Hospital of Wenzhou Medical University
Phase 1 Unknown
NCT03528421 2018-07-16
Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown
NCT02924753 2017-12-29
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Henan Cancer Hospital
Phase 1 Unknown
NCT03263208 2017-10-20
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
Henan Cancer Hospital
Phase 1/2 Unknown
NCT03208556 2017-09-14
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
Peking University
Phase 1 Unknown
NCT03146533 2017-05-17
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
Shenzhen Second People's Hospital
Phase 1/2 Unknown
NCT03044743 2017-05-02
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Unknown
NCT02685670 2017-03-16
MatchCART
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Phase 1/2 Unknown
NCT00209209 2017-03-07
MCLelderly
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT03016988 2017-01-11
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
Fujian Medical University
Phase 2 Unknown
NCT02933775 2016-10-14
CD19-redirected Autologous Cells (CAR-CD19 T Cells)
RenJi Hospital
Phase 1 Unknown
NCT02894645 2016-09-30
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
National University Hospital, Singapore
Phase 4 Unknown
NCT01423500 2015-06-26
ALL-SCT-BFMi
St. Anna Kinderkrebsforschung
Phase 3 Unknown
NCT01423747 2015-06-26
Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia
St. Anna Kinderkrebsforschung
Phase 3 Unknown
NCT02156726 2014-06-05
Q-lite
Czech CLL Study Group
Unknown
NCT02049580 2014-01-30
Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas
Istituto Clinico Humanitas
Phase 2 Unknown
NCT01983761 2013-11-18
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Targazyme, Inc.
Phase 1/2 Unknown
NCT00737685 2012-03-26
Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)
The Korean Society of Pediatric Hematology Oncology
Phase 2 Unknown
NCT01322776 2011-03-25
Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT00840385 2010-09-15
FAD
Fudan University
Phase 2 Unknown
NCT00815568 2008-12-30
Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)
Samsung Medical Center
Phase 2 Unknown
NCT00807196 2008-12-11
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
Maisonneuve-Rosemont Hospital
Phase 1/2 Unknown